大和:下調友邦保險(1299.HK)目標價至96港元 評級“買入”
大和發表研究報告指,武漢新型冠狀病毒肺炎持續蔓延,業務的暫停,尤其是面對面會議的減少,而會議是尋求新業務的最有效方法,相信將對代理的分配造成重大打擊。大和下調友邦保險(1299.HK)目標價2.04%,由原來的98港元降至96港元,評級維持“買入”不變。
大和表示,自1月底以來,香港政府已大幅收緊跨境交通,預料內地旅客數目將會大幅減少。由於友邦中國銷售的大多數產品都是關於重大疾病,而新型冠狀病毒並不包含在內,因此索賠的影響應該會降至最低。
該行預料,友邦2019年新業務價值將有9%增長,較市場預期高1個百分點。受中國業務推動,去年第4季的新業務價值將按年增長3%,而香港則按季略有回升。同時該行預計,集團2019年的內含價值(EV)將有14%的增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.